Plasma cell leukemia (PCL) is an aggressive variant of multiple myeloma characterized by a high level of plasma cells circulating in the peripheral blood. The prognosis of PCL patients treated with conventional chemotherapy remains poor. Some reports have suggested that both bortezomib and lenalidomide are effective in treating PCL. We herein report a case of primary PCL in which the patient achieved stringent complete remission after receiving combination chemotherapy with reduced-dose bortezomib, lenalidomide and dexamethasone (VRd). This regimen was very effective, and no severe adverse events were observed. A reduceddose VRd regimen can be considered in PCL patients.
Introduction
Plasma cell leukemia (PCL) is a rare, yet aggressive form of multiple myeloma characterized by a high level of plasma cells circulating in the peripheral blood. PCL can be classified as either de novo 'primary PCL' or 'secondary PCL,' which is a leukemic transformation of multiple myeloma (1) . The prognosis of PCL patients treated with conventional chemotherapy remains poor, with a median survival ranging from two to 12 months (2, 3). Autologous or allogenic stem cell transplantation is currently recommended for eligible patients with PCL, and long-term survival has occasionally been reported (4, 5) . Both bortezomib and lenalidomide are approved for the treatment of advanced multiple myeloma. Recently, the efficacy of bortezomib was also observed in a series of patients with newly diagnosed or relapsed PCL (6) (7) (8) . Some reports have suggested that lenalidomide is effective in patients with relapsed PCL (9-11). Bortezomib and lenalidomide have different mechanisms of anti-plasma cell dysplasia activity (12, 13) . The synergistic effects of dexamethasone are observed with both bortezomib and lenalidomide (12, 13) . We herein present a case of primary PCL in which the patient achieved stringent complete remission after receiving combination chemotherapy with reduced-dose bortezomib, lenalidomide and dexamethasone.
Case Report
A 49-year-old man was transferred to our institution with severe fatigue, dyspnea and multiple bone pain. On admission, a biochemical examination revealed hypercalcemia (15.2 mg/dL), an elevated creatinine level (2.37 mg/dL) and a low immunoglobulin level. The serum immunoglobulin levels of all isotypes were low. A peripheral blood count showed a hemoglobin level of 11.6 g/dL, a platelet count of 22.1×10 9 /L and a white blood cell count of 25.9×10 9 /L. A peripheral blood smear revealed 42% plasma cells with a few cytoplasmic vacuoles, as shown in Figure. was then initiated. After the second course of VRd therapy, the percentage of plasma cells in the bone marrow decreased to 1.9% and urine serum immunofixation electrophoresis indicated the disappearance of Bence Jones proteins. A follow-up bone marrow assessment completed after the sixth course of VRd therapy showed an absence of phenotypically aberrant plasma cells in the bone marrow on multiparameter flow cytometry. The serum free kappa to lambda light chain ratio also normalized. The patient was in stringent complete remission without any severe adverse events based on the International Myeloma Working Group (IMWG) criteria. He underwent bone marrow stem cell transplantation from an HLA-matched unrelated donor with fludarabine (150 mg/ m 2 ), melphalan (140 mg/m 2 ) and TBI (3 Gy) as a conditioning regimen. Twenty months after the PCL diagnosis, the patient remains in stringent CR.
Discussion
Recent reports have indicated that new drugs, in particular, bortezomib and lenalidomide, can significantly improve the clinical course of PCL. A retrospective survey of 12 patients with PCL treated with bortezomib showed an initial response rate of 92% (8) . Despite this dramatic initial efficacy, the duration of response to bortezomib was not long. Moreover, some reports have demonstrated the effectiveness of lenalidomide in patients with PCL; however the effects were also often temporary (9, 11) . It has been suggested that dexamethasone exerts synergistic effects on both bortezomib and lenalidomide. Under this premise, it is believed that the most promising results can be obtained from a three-drug regimen consisting of bortezomib, lenalidomide and dexamethasone. In fact, bortezomib, lenalidomide and dexamethasone combination therapy (VRD regimen) is highly effective in the treatment of newly diagnosed myeloma (14) . There have been only two case reports of PCL patients treated with VRD therapy (15, 16) (Table) . One case was primary PCL and two cases were secondary PCL. Goyal et al. reported the first primary PCL patient who obtained a complete remission after receiving combination chemotherapy with bortezomib, lenalidomide and dexamethasone (15) . However, the details of the treatment regimen and the patient's clinical course were not described. On the other hand, Gozzetti et al. reported two secondary PCL cases in detail (16) . The two patients were treated with a VRD regimen and obtained complete remission. However, one patient developed grade 3 neutropenia and pneumonia. Due to therapy discontinuation, he suffered disease recurrence and thereafter died.
The VRD regimen currently used usually consists of 3-week cycles of bortezomib at a dose of 1.3 mg/m 2 (on days 1, 4, 8 and 11), lenalidomide at a dose of 25 mg (days [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] and dexamethasone (40 or 20 mg on days 1, 2, 4, 5, 8, 9, 11 and 12). However, peripheral neuropathy is one of the most critical toxicities of bortezomib and often leads to dose modification and drug discontinuation. Bortezomib-induced peripheral neuropathy appears to be dependent on the dose and related to treatment exposure (17) . A recent study reported that once-weekly bortezomib is equally effective to and better tolerated than the standard twice-weekly bortezomib when administered in combination chemotherapy with melphalan-prednisolone ± thalidomide (18) . The most frequently seen toxicity of lenalidomide is myelosuppression, which can usually be managed with dose reduction. A phase 2 trial of relapsed or refractory multiple myeloma patients showed that lower doses of lenalidomide (15 mg) plus low-dose dexamethasone (40 mg weekly) significantly reduce the incidence of hematologic toxicities (from 15-30% to 2-13%), infections (from 20% to 8%) and thromboembolism (from 20% to 5%) (19) . In relapsed or refractory multiple myeloma patients, long-term continuous treatment may be more important for achieving optimal efficacy than the initial response to both lenalidomide-containing regimens and bortezomib-containing regimens (20, 21) . Discontinuation of chemotherapy due to adverse events can be lethal in patients with highly aggressive malignancies, such as plasma cell leukemia. Therefor, we chose reduced-dose bortezomib (1.3 mg/m 2 on days 1, 8 and 15), lenalidomide (10 mg for 21 days) and dexamethasone (20 mg weekly) to prevent therapy discontinuation. The reduced-dose VRd therapy was very effective, and only grade 1 hematological toxicity (anemia) was observed. We conclude that the reduceddose VRd regimen is well-tolerated and effective and can be used in patients with plasma cell leukemia.
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